187 related articles for article (PubMed ID: 33332932)
21. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma.
Duletić-Nacinović A; Stifter S; Marijić B; Lucin K; Valković T; Petranović D; Jonjić N
Tumori; 2008; 94(4):511-7. PubMed ID: 18822687
[TBL] [Abstract][Full Text] [Related]
22. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
Wang Q; Qin Y; Zhou S; He X; Yang J; Kang S; Liu P; Yang S; Zhang C; Gui L; Sun Y; Shi Y
Oncotarget; 2016 Nov; 7(44):72219-72228. PubMed ID: 27750215
[TBL] [Abstract][Full Text] [Related]
24. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
26. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
[TBL] [Abstract][Full Text] [Related]
27. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
28. Circulating low CD4
Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
[TBL] [Abstract][Full Text] [Related]
30. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of β₂-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma.
Yoo C; Yoon DH; Yoon S; Kim S; Huh J; Park CJ; Lee SW; Suh C
Leuk Lymphoma; 2015 Mar; 56(3):688-93. PubMed ID: 24913511
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
Chen-Liang TH; Martín-Santos T; Jerez A; Rodríguez-García G; Senent L; Martínez-Millán C; Muiña B; Orero M; Teruel A; Martín A; Gómez-Espuch J; Kennedy K; Benet C; Raya JM; Fernández-González M; de la Cruz F; Guinot M; Villegas C; Ballester I; Baile M; Moya M; López-Jiménez J; Frutos L; Navarro JL; Uña J; Fernández-López R; Igua C; Contreras J; Sánchez-Vañó R; Cozar MDP; Tamayo P; Mucientes J; Sánchez-Blanco JJ; Pérez-Ceballos E; Ortuño FJ
Cancer Med; 2017 Nov; 6(11):2507-2514. PubMed ID: 28960797
[TBL] [Abstract][Full Text] [Related]
33. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
34. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
[TBL] [Abstract][Full Text] [Related]
35. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma.
Chen NC; Chang H; Kao HW; Ou CW; Kuo MC; Wang PN; Lin TL; Wu JH; Hung YS; Su YJ; Ong YC; Shih HJ
Clin Exp Med; 2023 Nov; 23(7):3759-3766. PubMed ID: 37086332
[TBL] [Abstract][Full Text] [Related]
36. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
[No Abstract] [Full Text] [Related]
37. The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis.
Jiang T; Ding X; Lu W
Dis Markers; 2016; 2016():1523959. PubMed ID: 27110054
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
Qin C; Yang S; Sun X; Xia X; Li C; Lan X
Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
[TBL] [Abstract][Full Text] [Related]
39. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
[TBL] [Abstract][Full Text] [Related]
40. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
